NCT01369498 - Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

June 5, 2014

Study Completion Date

September 24, 2014

Conditions

Myelofibrosis

Interventions

DRUG

Simtuzumab

Simtuzumab administered intravenously over approximately 30 minutes every 2 weeks

DRUG

Ruxolitinib

In Stage 2, participants will be on a stable dose of ruxolitinib

Trial Locations (7)

Washington University in St. Louis, St Louis

MD Anderson Cancer Center, Houston

Mayo Clinic, Scottsdale

Stanford University Medical center, Stanford

Oncology Hematology Care Clinical Trials, Cincinnati

Cleveland Clinic, Cleveland

Tennessee Oncology, Nashville